Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.5 GBX | 0.00% | 0.00% | +18.27% |
Mar. 19 | Tissue Regenix annual loss narrows sharply as revenue jumps | AN |
Mar. 19 | Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M | MT |
Sales 2024 * | 27.11M 33.86M | Sales 2025 * | 31.03M 38.77M | Capitalization | 43.3M 54.09M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.69 x |
Net Debt 2024 * | 2.62M 3.27M | Net Debt 2025 * | 3.84M 4.8M | EV / Sales 2025 * | 1.52 x |
P/E ratio 2024 * |
-366
x | P/E ratio 2025 * |
147
x | Employees | 82 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.25% |
Current month | -1.60% | ||
1 month | -1.60% | ||
3 months | +7.89% | ||
6 months | +11.82% | ||
Current year | +18.27% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Lee
CEO | Chief Executive Officer | 63 | 18-12-31 |
Kirsten Lund
DFI | Director of Finance/CFO | - | 09-12-31 |
David Cocke
DFI | Director of Finance/CFO | 58 | 21-01-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Trevor Phillips
BRD | Director/Board Member | 63 | 21-01-04 |
George Phillips
BRD | Director/Board Member | 64 | 21-01-04 |
Daniel Lee
CEO | Chief Executive Officer | 63 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 61.5 | 0.00% | 61,694 |
24-04-25 | 61.5 | +2.16% | 53,466 |
24-04-24 | 60.2 | -2.11% | 47,682 |
24-04-23 | 61.5 | 0.00% | 19,970 |
24-04-22 | 61.5 | 0.00% | 15,013 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.27% | 53.94M | |
+4.36% | 32.47B | |
+14.14% | 7.45B | |
+22.93% | 3.89B | |
-16.29% | 3.15B | |
-25.96% | 1.28B | |
-36.14% | 1.09B | |
-35.42% | 902M | |
-0.13% | 893M | |
-24.12% | 857M |
- Stock Market
- Equities
- TRX Stock